top of page
Abstract Linear Background
lighthouse-pharma_logo_white transparent.png

Precision medicine for major unmet medical needs

About us

About Us

Changing the way we treat disease

Our approach leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders. We have a decade of data informing our strategy including patient responder analyses, rigorous dose modeling and flawless clinical execution. As a result, our therapeutic candidates have maximum potential for patient impact.

Screen Shot 2023-01-03 at 3.13.31 PM.png

News & Events

February 26, 2025

Lighthouse Pharmaceuticals Initiates Phase 2 SPRING Trial of LHP588 in P. gingivalis- positive Alzheimer’s Disease

 

48-Week Study to Evaluate the Safety and Efficacy of Oral LHP588 Dosed Once Daily

Nov 16, 2023

FDA Approval to Proceed with Phase 2 SPRING Trial of LHP588, a Next-generation Treatment for P. gingivalis-Positive Alzheimer’s Disease

- Phase 1 single ascending and multiple ascending dose studies previously completed demonstrate safety, tolerability and dosing to reach optimal target engagement

May 10, 2023

Lighthouse Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease

- Pre-IND meeting completed with US FDA. 

-World-class clinical advisory board to support clinical development plans

Team

Leadership Team

Screen Shot 2025-02-27 at 6.28.44 AM.png

Advisory Board

Screen Shot 2025-02-27 at 6.42.12 AM.png
Contact us
Screen Shot 2022-12-27 at 2.56.46 PM.png

Contact

Thanks for submitting!

bottom of page